ABSTRACT
Stem cells therapy holds a great promise to treat several degenerative diseases and repair damaged tissues that are otherwise very difficult to treat by conventional therapies. In future, stem cells therapy will treat spinal cord injury [SCI] which is a major problem associated with demyelination of neurons caused by trauma resulting in cell death that is irreplaceable. Patients usually survive with spinal cord injury but this trauma remains uncure. After SCI, endogenous neuroprogenitor cells migrate towards the affected tissue but many messenger cascades suppress their proliferative activity. Different exogenous stem cells sources are another option to treat SCI patients. Although there is no permanent cure of SCI patients but due to excitable development in the field of stem cells transplantation, promises a hope for its cure in future. Due to intricacy of factors involved after SCI, there is a need for combinatorial therapies
ABSTRACT
Thymosin alpha 1 [T alpha 1] is 28 amino acid residues peptide. Thymic epithelial cells produce acetylated N-terminal T alpha 1 that has powerful immunostimulatory and antitumor activites. Inside the body T alpha 1 effects endocrine, immune and central nervous system. T alpha 1 can be purified by using fractionation procedures from thymus. Many recombinant DNA techniques are being used for the production of T alpha 1. In addition T alpha 1 is being expressed as fusion proteins with other therapeutically important proteins. For the high-throughput production of T alpha 1, different expression systems are being used such as E.coli and yeast. T alpha 1 has unique antitumor and immunoregulatory properties and also have capacity to protect cells from oxidative damage. T alpha 1 has many therapeutic applications specifically against many infectious diseases [hepatitis B and C, AIDS, SARS etc.] and cancer